Figure 7.

TSAd regulates adherens junctions in vivo. (A) Cremaster muscles superfused for 30 min with vehicle (top) or with 100 ng/ml VEGF (middle), followed by whole-mount immunostaining with anti-VE-cadherin. Bottom panels show higher magnification of boxed region in middle panels. Representative images are shown. n = 6 WT mice and 4 tsad^−/− mice each for the basal and VEGF treatment conditions; a total of 20 mice. Each superfusion was performed independently. Images were inverted and linearly contrast stretched by 20%. Bars, 50 µm. (B) Percentage of junction outline localized at different distances from junction midline as defined by VE-cadherin immunostaining in cremaster muscles superfused with VEGF, as in A, for WT basal (blue), WT treated with VEGF (red), tsad^−/− basal (green), and tsad^−/− treated with VEGF (yellow). n = 6 WT mice for each condition and 4 tsad^−/− mice for each condition.